In this article:

Dawson James Maintains a Buy Rating on Anavex Life Sciences (AVXL)

In this article:
In this article:

Dawson James analyst Jason Kolbert maintained a Buy rating on Anavex Life Sciences (AVXLResearch Report) on November 24 and set a price target of $35.00. The company’s shares closed last Tuesday at $16.24.

According to TipRanks.com, Kolbert has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.

Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $39.80, implying a 123.0% upside from current levels. In a report issued on November 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $39.00 price target.

See the top stocks recommended by analysts >>

Anavex Life Sciences’ market cap is currently $1.23B and has a P/E ratio of -30.10.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Read More on AVXL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed